Data / Form D filings / X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc.: Form D filings
X4 Pharmaceuticals, Inc., a pharmaceuticals company in Cambridge, MA, filed 4 Form D notices with the SEC between 2015 and 2018. The latest, on September 21, 2018, reports $35 million sold of a $35 million offering to 214 investors.
Find out what X4 Pharmaceuticals, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 955 Massachusetts Avenue, Cambridge, MA, 02139
- Phone
- (339) 203-1076
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2014
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1632304
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 21, 2018 | Amendment | $34,999,150 | $34,999,150 | $0 | 214 | Nov 1, 2017 | sec.gov |
| Nov 15, 2017 | New notice | $30,000,000 | $25,838,812 | $4,161,188 | 213 | Nov 1, 2017 | sec.gov |
| Aug 28, 2015 | New notice | $37,500,000 | $37,499,999 | $1 | 220 | Aug 14, 2015 | sec.gov |
| Jan 30, 2015 | New notice | $1,200,000 | $735,000 | $465,000 | 11 | Jan 16, 2015 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Adam Mostafa | Executive Officer | |
| Michael Gilman | Director | |
| Paula Ragan | Executive Officer, Director | |
| Michael Wyzga | Director | |
| Isaac Blech | Director | |
| Alan E. Walts | Executive Officer, Director |
Other pharmaceuticals companies in Massachusetts that filed recently
- BridgeHealth Pharmaceuticals, Inc. $3.5 million · Nov 5, 2026
- Land Therapeutics Inc. $17.5 million · Oct 21, 2026
- Crosslink Therapeutics Inc. $5.5 million · Oct 20, 2026
- Sentonix, Inc. $12.7 million · Aug 20, 2026
Every Form D from the week of Sep 17, 2018 · All recent filings in Massachusetts · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what X4 Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.